The combined presence of TNNC1+ and M2+ exacerbates the adverse impact on LUAD patient survival, suggesting that TNNC1 not only affects disease progression through direct action on tumor cells but also exerts indirect influence by regulating the tumor immune microenvironment. Here, TNNC1 is linked to neoplasm.